Premium
Survival in 222 adult patients with acute leukaemia treated with intermittent combination chemotherapy programme
Author(s) -
Evensen S.A.,
Stavem P.,
Lund E.
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb00799.x
Subject(s) - medicine , chemotherapy , survival rate , cumulative dose , adverse effect , induction chemotherapy , acute lymphocytic leukemia , pediatrics , surgery , leukemia , lymphoblastic leukemia
222 patients aged 15–59 years with acute leukaemia were treated with intermittent combination chemotherapy consisting of six 5‐day courses of cytotoxic drugs as induction treatment followed by 3 years of maintenance therapy in patients who obtained complete remission (CR). CR was achieved in 50.3% of 161 patients (early deaths included) with acute myelogenous leukaemia (AML). The observed cumulative 5‐yr survival rate (observation time 1–12.25 yr) calculated by the life table method was 12% in AML. Among patients who obtained CR, those aged 40–59 yr appeared to fare better than younger patients (5‐yr survival: 24%). The M‐3 subtype was an adverse prognostic factor. In acute lymphoblastic leukaemia (ALL) the CR rate was 83.6% and the observed cumulative 5‐yr survival rate was 14%. Women fared better than men.